Stay updated on Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.

Latest updates to the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page revision tag was updated to v3.5.4, replacing the previous v3.5.3 to reflect a new version of the study record.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedThe page footer version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a site/software update rather than a change to the clinical study information.SummaryDifference0.1%

- Check49 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0.SummaryDifference0.1%

- Check56 days agoChange DetectedNo substantive changes detected in the study record; the study details and eligibility criteria appear unchanged.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision: v3.5.0 updated from the previous v3.4.3.SummaryDifference0.1%

- Check91 days agoChange DetectedAdded Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.1%

Stay in the know with updates to Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neo-adjuvant Pembrolizumab in Stage IV Ovarian Cancer Clinical Trial page.